Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO

Executive Summary

Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say
Advertisement

Related Content

Daiichi Gets Into Generics With Stake In Ranbaxy
Bristol Recharges Kai Heart Attack Candidate
Bristol Recharges Kai Heart Attack Candidate
Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs
Pharmaceutical Strategic Alliances: Sharing and Optimizing Risk
Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors
Advertisement
UsernamePublicRestriction

Register

PS049830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel